Both thyroid hormone and hypothalamic growth hormone (GH)-releasing factor (GRF) facilitate pituitary somatotroph function. However, the pathophysiological role of thyroid hormone in GRF secretion is less well understood. Thyrotoxicosis, induced by administration of thyroxine (T4) in rats, inhibited both pituitary GH levels and immunoreactive GRF secretion from incubated hypothalamus. At the highest dose of T4 given for 12 d, GRF secretion and pituitary GH decreased by 50 and 39%, respectively. Hypothyroidism induced by thyroidectomy (T.) enhanced GRF secretion approximately twofold while depleting pituitary GH by > 99%. Both, of these hypothalamic and pituitary effects were reversed by replacement of T4 but not human GH for 7 or 14 d. Human GH was as potent as T4 in restoring decreased body weight gains or serum insulin-like growth factor-i levels in T. rats. These results indicate that at both physiological and pathological concentrations in serum, thyroid hormone acts as an inhibitory modulator of GRF secretion, probably not involving a feedback mechanism through GH. A biphasic effect of thyroid hormone on pituitary GH levels appears to derive from the difference in primary target tissues of hyper-and hypothyroidism, the hypothalamus and the pituitary, respectively. (J. Clin. Invest. 1992.90:113-120.) 
Introduction
Secretion ofpituitary growth hormone (GH)' is positively regulated by the hypothalamic peptide, GH-releasing factor (GRF) (1) (2) (3) . GRF generates spontaneous bursts ofGH secretion (4) (5) (6) and also increases GH gene transcription and GH mRNA levels (7, 8) . Somatostatin (SRIF) is the hypothalamic peptide 1 . Abbreviations used in this paper: BW, body weight; GH, growth hormone; GRF, GH-releasing factor; hGH, human GH; HKRB, Hepes-buffered Krebs-Ringer bicarbonate solution; IGF-I, insulin-like growth factor-I; SRIF, somatostatin; T3, triiodothyronine; T4, thyroxine; TX, thyroidectomy or thyroidectomized.
that inhibits GH secretion (9, 10) and may be also involved in the regulation of GRF secretion within the hypothalamus ( 1 1, 12) . Although GRF and SRIF play a primary role in GH secretion, there are other important hormones that modulate pituitary GH secretion, probably through effects on the GH-regulatory peptides, GRF and/or SRIF. These include thyroid hormone, adrenal glucocorticoid, and gonadal steroid of peripheral endocrine organs (13) . The most important for growth and development of mammals is thyroid hormone. Thyroid hormone stimulates synthesis and secretion of GH (14) (15) (16) and also increases GH gene transcription and GH mRNA levels ( 17-19). Hypothyroidism depletes pituitary GH (14) (15) (16) , inhibits GH secretion (20) (21) (22) , and causes severe growth retardation (23) .
Thus, both thyroid hormone and GRF directly stimulate pituitary somatotroph function, and their hypophyseal actions are similar in many aspects. However, the pathophysiological role ofthyroid hormone in hypothalamic GRF secretion is less well understood. It appears more complex because GRF receives a negative feedback signal from GH (24) (25) (26) (27) , so thyroid hormone might influence GRF secretion indirectly through the effect on pituitary GH. Furthermore, thyroid hormone has a biphasic effect on growth rate. In immature animals and young patients, growth is retarded by hypothyroidism, is restored by replacement doses ofthyroxine (T4), and is inhibited by thyrotoxic doses of T4 (28) . We and others previously reported that thyroidectomy (T,) enhanced in vitro secretion of hypothalamic GRF in rats (26, 29) . Whether this effect is caused by thyroid hormone deficiency per se or mediated through associated GH deficiency remains unknown. Also unknown is the effect of hyperthyroidism on GRF secretion.
In the present studies in rats, we have compared effects of thyroid hormone excess and deficiency in vivo on hypothalamic GRF secretion in vitro. To examine the mechanism of action of hypothyroidism, we have investigated whether the TX-induced rise in GRF secretion is reversible by replacement of T4 or human GH (hGH). We have also studied effect of hGH in combination with T4, because GH given with T4 promotes the growth of thyroid-deficient animals more than GH alone (23, 30) . In experiments with hGH, serum levels ofinsulin-like growth factor-I (IGF-I) as well as body weight gains were measured as an index of a biological effect of hGH. Finally, we have characterized GRF secreted in the medium to examine whether an abnormal thyroid status alters a molecular form of GRF. and trifluoroacetic acid (TFA) from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Synthetic rat GRF was purchased from Peninsula Laboratories, Inc. (Belmont, CA).
Animals and experimental protocols
Male Sprague-Dawley rats were obtained from Japan SLC Inc. (Hamamatsu City, Shizouka, Japan) at 5 wk of age. They were housed in a room under controlled temperature (22±1 0C), humidity (50-55%) and light/dark conditions (lights on 0800-2000 h). Food and water were available ad libitum.
Hyperthyroidism was induced at 10-1 1 wk of age by subcutaneously injecting T4 once daily for 6 or 12 d. Animals were weighed daily at 1700-1730 h, and T4 was given on a daily weight basis in doses of25, 50, or 100 ,g/ 100 g body weight (BW). An intermediate 50 ,ug/ 100 g BW dose of T4 was the dose that inhibited BW gain but did not reduce pretreatment BW, according to the results ofa preliminary experiment. T4 was dissolved in 50% propyleneglycol and diluted four times with 0.0033 N NaOH before subcutaneous administration. Control rats received vehicle injection. The animals were killed by decapitation 20 h after the last injection. Hypothalamic tissues were obtained for subsequent incubation experiments and anterior pituitaries for GH measurement. The trunk blood was also collected in experiments in which T4 or vehicle was administered for 12 d.
Hypothyroidism was produced by surgical thyroidectomy (T.) at 6 wk of age. Because parathyroidectomy attenuates pulsatile GH secretion in rats ( 31 ) , at least three parathyroid glands were left, and calcium was not supplemented in drinking water. From 4 wk after operation, T, rats were replaced once daily with a "physiological" dose ofT4
(1 or 2 ,g/ 100 g BW) or treated twice daily with hGH ( 100 ig/rat) for 7 d. hGH was dissolved in physiological saline. In the next experiments, T. rats received the same treatments for 14 d. Finally, we investigated whether hGH could affect GRF secretion synergistically with thyroid hormone. TX rats were supplemented with T4 alone (2 ,g/ 100 g BW, once daily) or in combination with hGH (100 ag/rat, twice daily) for 7 d. T4 was injected subcutaneously at 1730-1800 h and hGH at 0830-0900 h and 1730-1800 h. Control TX and sham-operated rats were treated with vehicles for T4, hGH, or both. The animals were decapitated 18 h after the last injection; and the hypothalamus, anterior pituitary, and trunk blood were collected.
Hypothalamic incubation
The method of hypothalamic incubation has been described elsewhere (24) . In brief, the brain was obtained after cutting the pituitary stalks carefully, and the hypothalami were cut sagittally through the median eminence with the ventral surface up. The area between the posterior border of the optic chiasma, the anterior border of the mammillary body, the lateral hypothalamic sulcus, and 2 mm deep from the ventral surface was dissected into two fragments. The fragments were placed in polyethylene vials containing 0.6 ml of 11 mM Hepes-buffered KrebsRinger bicarbonate solution (HKRB), pH 7.40, which was pregassed with 95% 02-5% CO2 and supplemented with 5.5 mM glucose, 0.1% BSA, and 500 mg/ml bacitracin. Four hypothalamic fragments from two rats were incubated in one vial. All incubations were 30 min at 37°C under an atmosphere of95% 02-5% CO2 in a shaking water bath (60 cycles/min). After preincubation, the tissues were incubated in HKRB (basal secretion) and then in 50 mM K+-containing HKRB (K+-stimulated secretion). The medium was collected every 30 min and replaced with fresh buffer. The collected medium was centrifuged at 3,000 rpm for 5 min at 4°C, and the supernatants were quickly frozen on dry ice and kept at -20°C until assayed. Each hypothalamic incubation used 18-24 animals, and a secretion experiment consisted of two to three separate incubations.
Tissue extraction
Immediately after the hypothalamic incubations, four hypothalamic fragments were pooled and GRF in the tissues was extracted as described (24 RIAsfor rat GRF, GH, T4, and IGF-I GRF in the medium and tissue samples was determined by RIA as described elsewhere (24) . The minimum detectable dose (BO-2SD) was 2 pg/tube, with half-maximal displacement of22-25 pg/tube. The nonspecific binding was < 2%. The samples were measured directly without extraction or concentration. In assays ofthe medium samples, HKRB buffer was added to all standard curves in a volume of 100-200 tL equivalent to that ofthe unknown. The total incubation volume was 500,u. Pituitary GH contents were measured in duplicate by a specific rat GH RIA (5, 12, 24) at two dilutions using materials provided by the Rat Pituitary Hormone Distribution Program, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health. Results were expressed in terms of NIDDK rat GH RP-2 reference standard. Serum T4 levels were determined by a double antibody method with a RIA kit purchased from Eiken ICL (Tokyo, Japan). The sensitivity ofthe T4 assay was 1 Ag/dl. Serum IGF-I levels were measured by RIA as described (33) , using biosynthetic human IGF-I as standards and an antiserum not cross-reactive with IGF-II. Serum samples were extracted by the aceton-formic acid method of Bowsher et al. (34) . The least detectable level of IGF-I assay was 10 pg/tube.
Data analysis
Results were expressed as means±SE. Analysis ofvariance was used for statistical analysis. Relationship between serum T4 and GRF secretion in hyperthyroid rats was analysed using linear regression analysis. Subsequent to analysis of variance, the significance of differences between experimental groups was determined by the Student-Newman-Keuls test. A P value of < 0.05 was considered statistically significant. 
Results
Effects ofhyperthyroidism on hypothalamic GRF, pituitary GH, and serum T4 (Table I) . Both effects were dose related, and the inhibitory effect on GRF secretion was greater than that observed after 6 d of T4 administration. Basal GRF secretion was inhibited below the assay detection limit (P < 0.01) by both of the 50 and 100 ug/ 100 g doses. K+-evoked GRF secretion was suppressed by 10.3% (NS), 27 .3% (P <0.0l),and5o.1%(P<0.00l)bythe25,50,and l0,g/100 g doses of T4, respectively. Linear regression analysis showed a significant negative relationship (r = -0.77, P < 0.0001) between serum T4 levels and K+-evoked GRF secretion (data not illustrated). The T4-induced suppression of GRF secretion after 12 d was associated with a parallel dose-related decline in pituitary GH ( Table I ). The decline in GH was significant at an intermediate dose of T4 (-18.5%, P < 0.01), and the minimum GH level at the highest dose was 60.7% (P < 0.001) of the control value. T4 at the highest dose also reduced pituitary GH after 6 d, but to a lesser extent (-10.6%, P < 0.05) than after 12 d (Table I) . Hypothalamic GRF contents were diminished only after administration of the highest dose for 12 d (-16.4%, P < 0.05) ( Table I) .
At the beginning ofT4 treatment for 12 d, mean (±SE) BW of all animals was 378±5 g (n = 90), and those after treatment were 412±4 (n = 26), 399±6 (n = 14), 366±7 (n = 26), or 329±6 g (n = 24) (P < 0.001 vs. initial weight) in rats given 0 (vehicle), 25, 50, or 100,ug T4/100 g per d, respectively. After administration of T4 for 6 d, the initial BW was significantly decreased also at the highest dose only (-7.6%, P < 0.01).
Effects of hypothyroidism and T4 or hGH replacement on hypothalamic GRF secretion in vitro As shown in Fig. 2 Tx rats were then replaced with T4 or hGH for 14 d at the same daily dose (Fig. 3) TX depleted pituitary GH contents to < 1% ofthat ofeuthyroid rats (P < 0.001 ) at 5-6 wk after operation, and the reduced pituitary GH was significantly (P < 0.001 ) reversed by T4 (Table III). This reversibility was greater by replacement of T4 at a higher dose (2 vs. 1 ,ug/ 100 g per d) when the length of treatment was same, or by replacement for a longer duration ( 14 vs. 7 d) when the dose ofT4 was same. With the replacement ofT4 at 2 ,ug/ 100 g per d for 14 d, the decreased pituitary GH was restored to the maximum level of 82% of that of sham TX rats, although this level remained significantly lower (P < 0.001) than the euthyroid value.
Characterization ofhypothalamic GRF in the medium The inhibition of GRF secretion by thyroid hormone occurs at physiological concentrations in serum. This is indicated by the findings that thyroid gland ablation enhanced GRF secretion and that this effect was highly reversible by replacement of T4 at physiological doses. Also, at thyrotoxic doses, T4 suppressed GRF secretion in normal rats. These effects of thyroid hormone status on GRF secretion are probably not simply the result of weight changes or altered food intake. First, hyperand hypothyroidism similarly diminished BWs, while exhibiting an opposite effect on GRF secretion. Second, the inhibition of GRF secretion by thyrotoxicosis was already significant at Thyroid Hormone and Growth Hormone-releasing Factor 117 (35), whereas food deprivation decreases GRF mRNA levels (36) and GRF secretion in the rat (unpublished observation). Therefore, if thyroid hormone acted by altering food intake, it would have been the hypothyroid but not hyperthyroid rats who showed the diminished GRF secretion.
Consistent with a modulatory role in GH secretion, the effect that thyroid hormone exerted on GRF secretion was ofa delayed type at both physiological and thyrotoxic doses. Although the decreased GRF contents in hypothyroid rats were fully recovered after 7 d ofT4 replacement, the enhanced GRF secretion was not completely reversed after either 7 or 14 d of replacement. T4 was without effect on GRF secretion when replaced for 4 d in TX rats (26) . The suppression ofGRF secretion in hyperthyroid rats was greater after administration ofthe highest dose ofT4 for 12 than 6 d, and the dose-response relationship became apparent after 12 d. These results suggest that the effectiveness of thyroid hormone on GRF secretion is determined by the duration of its treatment as well as the dose administered.
It is well established that hypothyroidism causes a severe depletion ofpituitary GH (14) (15) (16) . As soon as 6 h after replacement, T4 can start to increase the diminished GH (16), whereas little is known on a precise time course of its recovery to euthyroid level. The present studies give some information on this issue by replacing T4 at physiological doses of 1 or 2 ,g/ 100 g, each for 7 and 14 d. However, replacement ofT4 for 14 d was not sufficient to recover the diminished GH content completely. This is consistent with a morphological study of DeFesi et al. that 17-24 d of triiodothyronine (T3) replacement was required to normalize decreased somatotroph number in TX rats (37) . In contrast, diminished GH secretion in TX rats was normalized within 4 d after initiation of T4 replacement (22). These findings, together with the present results on GRF, indicate that it takes > 14 d for replacement of T4 to normalize the whole of the altered hypothalamic GRF-pituitary GH axis in hypothyroid rats.
In addition to depleting pituitary GH contents, hypothyroidism also abolishes spontaneous GH secretion (20) (21) (22) , suppresses GH response to GRF (38) (39) (40) , and causes growth retardation (23) . Qualitatively similar effects can be reproduced by GRF antibodies (4) (5) (6) 41 ) or its antagonists (42, 43 (26, 29) . We conclude, therefore, that the pituitary somatotroph failure in hypothyroidism is not caused by GRF deficiency and so most probably is a direct consequence of thyroid hormone deficiency. The same conclusion was obtained also in an in vivo study with neonatal hypothyroid rats (44) .
The effect of hyperthyroidism on the hypothalamic-pituitary GH axis has been less clear. There is some evidence to suggest that thyrotoxicosis has an inhibitory influence on GH. Hyperthyroidism causes a moderate decline in both pituitary GH and BWs in the neonatal rat (45, 46) . Physiological GH secretion was diminished in human subjects with thyrotoxicosis and was normalized after they became euthyroid (47) . The present studies have demonstrated that hyperthyroidism inhibits GRF secretion, concomitantly decreasing both BWs and pituitary GH in the adult rat. This finding, together with the report of Clark and Robinson (48) that GRF accelerates growth and increases GH content in rats, indicates that the decreased in vitro release of GRF in hyperthyroid rats is not due to an increased turnover rate of GRF in vivo. The parallel decline in GRF secretion, GH content, and possibly GH secretion as well suggests that the hypothalamus is a primary target 118 tissue of hyperthyroidism in GH secretion. This view is supported by the finding that pituitary GH responsiveness to GRF in vivo was not affected or only minimally decreased in hyperthyroid rats (49, 50) . Thus, at pathological conditions, thyroid hormone appears to negatively influence pituitary somatotroph function by two pathways: one in hyperthyroidism via the hypothalamus and the other in hypothyroidism leading directly to the pituitary. This difference in the primary target tissue could explain biphasic effects of thyroid hormone on growth rate (28) and pituitary GH contents.
At a supraphysiological concentration of 1.55 X 10-6 M, the addition of T3 stimulates hypothalamic SRIF secretion in vitro (51 ) . This effect is inhibitory for pituitary GH secretion, as was the effect that thyroid hormone excess exerted on GRF in the present studies. Hyperthyroidism may depress pituitary GH secretion through a dual effect on GRF and SRIF in the hypothalamus. Modulation of SRIF by thyroid hormone deficiency is conflicting. Hypothalamic SRIF secretion in vitro is reported to be decreased (51), unaltered (21), or enhanced (29) in hypothyroid rats. This may be due in part to the difference in the induction time or length of hypothyroidism or in the method of operation, thyroidectomy vs. thyroparathyroidectomy. Anyway, these discrepant studies seem to agree on that hypothyroid rats can continue to secrete a considerable proportion of SRIF, if its capacity is even decreased. However, it remains unknown whether SRIF inhibition ofGH secretion is of any significance in severe hypothyroidism, in which GH is virtually absent in the bloodstream.
With replacement of hGH, we could not reverse the enhanced GRF secretion associated with GH deficiency in hypothyroid rats. At the dose and duration used, hGH was as potent as T4 in restoring decreased body weight gains of T. rats. hGH also restored the diminished serum levels of IGF-I, a mediator of anabolic effects of GH (52). The effect of hGH on IGF-I induction was comparable to that of T4 after 14 d of replacement, although not significant after 7 d. This finding agrees well with the earlier reports on hypothyroid adult rats treated with bovine GH for 7 d (53) or hGH for 14 d (54) . Furthermore, unlike the effect on growth (23, 30, 55) , a combined hGH and T4 therapy was not more effective than T4 alone in inhibiting GRF secretion in hypothyroid rats. These results suggest that the increased GRF secretion in hypothyroidism is not mediated through the feedback mechanism involving either GH or IGF-I deficiency.
There is biochemical evidence to support that thyroid hormone acts directly at the level of the hypothalamus. The conversion of T4 to its active metabolite T3 is an important step in mediating the action of thyroid hormone on its nuclear receptor and has been considered the main source of T3 in the brain ( 56, 57 ) . Type II 5 ' -monodeionase is an enzyme that deiodinates T4 to T3 in the brain (56) , and the activity of this enzyme is highest in the arcuate nucleus and median eminence in brains of hypothyroid rats (58) . Because these hypothalamic regions possess both cell bodies and nerve terminals of the hypophysiotrophic GRF neurons (59, 60), T3 generated locally in the hypothalamus could directly influence the functional activity of GRF neurons. This view may be supported by the significant correlation between serum T4 levels and GRF secretion that we observed in hyperthyroid rats. Alternatively, thyroid hormone may act indirectly through altering metabolic and/or other factors of the central or peripheral origin.
Other laboratories have recently reported that hypothalamic GRFmRNA levels in rats were increased in hypothyroidism (26, 27, 61 ) and decreased in hyperthyroidism (61) . This negative relationship between GRF mRNA and thyroid function is similar to that which we found between GRF secretion and serum T4. In their studies on hypothyroid rats, however, GH showed an inhibitory effect on GRF mRNA levels, whereas we observed that GH was without effect on GRF secretion. The increased GRF mRNA levels were completely reversed by 5 d of rat GH replacement in adult hypothyroid rats, and rat GH was more potent than T4 (26) . It was also reversed by hGH in prepubertal hypothyroid rats, although 14 d of replacement was required for complete reversel (27) . Thus, thyroid hormone modulates GRF mRNA levels and peptide secretion in a similar inhibitory mode. However, the underlying mechanisms are probably different, involving the GH feedback for GRF mRNA but not for GRF peptide secretion. Alternatively, GRF secretion might be less sensitive than GRF mRNA to the GH feedback signal or could respond to GH administered in a physiological pulsatile pattern only.
